Predicting pregnancy complications with high-plex proteomics
A SomaLogic boutique webinar
Predicting pregnancy complications with high-plex proteomics
The interdisciplinary team, comprising 10-15 scientists and clinician-scientists, is dedicated to advancing diagnostics and therapeutics aimed at enhancing maternal and fetal care. Their primary focus lies in the development of interventions for conditions such as ectopic pregnancy and preeclampsia, alongside the creation of diagnostics to prevent stillbirth. In this webinar, Dr. Lucy Bartho delves into the transformative role of SomaLogic’s SomaScan® assay in their biomarker discovery endeavors. She will also elaborate on how this technology has facilitated the development of clinical tools for the early identification of preeclampsia and fetal growth restriction.
Lucy Bartho, PhD
Dr. Lucy Bartho is a postdoctoral fellow from the Translational Obstetrics Group at the University of Melbourne, co-led by Professor Stephen Tong and Professor Tu’uhevaha Kaitu’u-Lino. The team of 10-15 scientists and clinician-scientists is dedicated to developing diagnostics and therapeutics aimed at enhancing the care of pregnant women and their fetuses. The research arising from the team focuses on identifying novel biomarkers for predicting pregnancy complications, developing treatments for ectopic pregnancy and preeclampsia, and elucidating the pathogenesis of these conditions.
Predicting pregnancy complications with high-plex proteomics
A presentation by Lucy Bartho, PhD
More webinars
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.
WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.
WebinarSerum Autoantibodies Differentiate Rheumatoid Arthritis Subgroups
Patients with rheumatoid arthritis (RA) can be categorized as either anti-citrullinated protein antibody-positive (ACPA+) or negative (ACPA-). In this webinar, Dr. Sung will present his research exploring a broad range of serological autoantibodies to uncover immunological differences between these RA subgroups using data from ACPA+ RA patients, ACPA- RA patients, and matched healthy controls.